Neoadjuvant Carboplatin/Paclitaxel versus 5-Fluorouracil/Cisplatin in Combination with Radiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter Comparative Study.
Xing GaoPing-Chung TsaiKai-Hao ChuangChu-Pin PaiPo-Kuei HsuShau-Hsuan LiHung-I LuJoseph Jan-Baptist van LanschotYin Kai ChaoPublished in: Cancers (2022)
The CROSS regimen conferred a significant survival benefit over PF4500, although the similar survival figures were similar to those observed with PF5040. Considering the lower incidences of severe weight loss and post-esophagectomy anastomotic leaks, CROSS represents a safe and effective neoadjuvant treatment for Taiwanese patients with ESCC.
Keyphrases
- rectal cancer
- locally advanced
- weight loss
- phase ii study
- lymph node
- free survival
- radiation therapy
- early stage
- bariatric surgery
- squamous cell carcinoma
- early onset
- type diabetes
- roux en y gastric bypass
- metabolic syndrome
- randomized controlled trial
- gastric bypass
- insulin resistance
- body mass index
- combination therapy
- replacement therapy
- obese patients